NCI FY25 operational task order
Ended Awarded Last action
- Contract number
- 75N91024F00011
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $398,925,093
Award facts
- Contract value 99% obligated
- $401,797,653.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $14,269,581 | |
| Other Administrative Action | $151,159 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $25,765,269 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $275,000 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $358,464,083 |
About this award
This is a $401,797,653 cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for operational task order work with an ultimate completion date of August 30, 2025. Leidos Biomedical Research Inc. is an experienced Federally Funded Research and Development Center (FFRDC) contractor for NCI, providing comprehensive biomedical research and facilities support services. The contract does not have a set-aside designation. The contract involves a wide range of activities supporting critical scientific research across multiple disease areas, including cancer, HIV/AIDS, influenza, COVID-19, and gene therapy. Leidos Biomedical Research Inc. is also known to collaborate with academic institutions on federal grant sub-awards for specialized research initiatives.
Quick answers
Who was awarded contract 75N91024F00011?
75N91024F00011 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 28, 2024.
How much is contract 75N91024F00011 worth?
The government has obligated $398,925,093 on 75N91024F00011. Its current value, with exercised options, is $401,797,653.
Is contract 75N91024F00011 an order under another contract?
Yes. 75N91024F00011 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91024F00011 competed?
The extent of competition for 75N91024F00011 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award